Evolution of advanced technologies in prostate cancer radiotherapy (Q38135708)

29 August 2017

title

Evolution of advanced technologies in prostate cancer radiotherapy (English)

1 reference

adaptive radiation therapy

29 August 2017

main subject

0 references

1 reference

7

1 reference

29 August 2017

Nicholas G Zaorsky

1

0 references

Timothy N Showalter

object named as

Timothy N Showalter

5

0 references

Robert B. Den

object named as

Robert B Den

8

0 references

Edouard J Trabulsi

3

object named as

Edouard J Trabulsi

1 reference

29 August 2017

Amy S Harrison

2

1 reference

29 August 2017

Leonard G Gomella

4

1 reference

29 August 2017

Mark D Hurwitz

6

1 reference

29 August 2017

language of work or name

English

0 references

publication date

10 September 2013

1 reference

29 August 2017

published in

Nature Reviews Urology

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

565-579

1 reference

International variation in prostate cancer incidence and mortality rates.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

External beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Clinical application of image-guided radiotherapy in bladder and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The current status of image-guided external beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Different styles of image-guided radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Intensity-modulated radiotherapy in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Is alpha/beta for prostate tumors really low?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Multimodality therapy for patients with high-risk prostate cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Interfraction rotation of the prostate as evaluated by kilovoltage X-ray fiducial marker imaging in intensity-modulated radiotherapy of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Gains from real-time tracking of prostate motion during external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Prostate intrafraction translation margins for real-time monitoring and correction strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The dosimetric impact of prostate rotations during electromagnetically guided external-beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Characterizing Interfraction Variations and Their Dosimetric Effects in Prostate Cancer Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

A comparison of the acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Magnetic resonance imaging-based treatment planning for prostate brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The effect of ethnicity and sexual preference on prostate-cancer-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

What hypofractionated protocols should be tested for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Investigating the dosimetric and tumor control consequences of prostate seed loss and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Current status and perspectives of brachytherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Prostate bed motion during intensity-modulated radiotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Systematic review of hypofractionated radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

What do we know about the α/β for prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The impact of fractionation in SBRT: analysis with the linear quadratic model and the universal survival curve model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Radiological Use of Fast Protons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Late gastrointestinal toxicities following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Carbon-ion radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Proton beam therapy and localised prostate cancer: current status and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Physician evaluation of internet health information on proton therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Protons for prostate cancer: the dream versus the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Observational methods in comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Comparative effectiveness research and personalized medicine: catalyzing or colliding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The body of evidence for advanced technology in radiation oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Effect of body mass index on intrafraction prostate displacement monitored by real-time electromagnetic tracking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

PET and PET/CT in radiation treatment planning for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

PET/CT Imaging and Radioimmunotherapy of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Functional magnetic resonance imaging in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Advances in magnetic resonance imaging: how they are changing the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Urethra sparing - potential of combined Nickel-Titanium stent and intensity modulated radiation therapy in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Genetic variants associated with predisposition to prostate cancer and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Establishment of a Radiogenomics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Disturbed colonic motility contributes to anorectal symptoms and dysfunction after radiotherapy for carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: importance of baseline symptoms and of prostate-V150.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Guideline for the management of clinically localized prostate cancer: 2007 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Natural history of early, localized prostate cancer: a final report from three decades of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Activity-based costing: a practical model for cost calculation in radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

21 January 2018

Costs of Radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Improved management of radiotherapy departments through accurate cost data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Is there more than one late radiation proctitis syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Ultra-High Dose (86.4 Gy) IMRT for Localized Prostate Cancer: Toxicity and Biochemical Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The 2010 NCCN clinical practice guidelines in oncology on prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Interfraction prostate rotation determined from in-room computerized tomography images

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Modern brachytherapy for treatment of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Impact of race on biochemical disease recurrence after prostate brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Extreme hypofractionation for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Phase I/II clinical trials of carbon ion therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Hypofractionated radiotherapy with carbon ion beams for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Technology evolution: is it survival of the fittest?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Cost accounting in radiation oncology: a computer-based model for reimbursement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.185

The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate.

31 March 2020

1 reference

12 December 2020

Cost, quality, and value in healthcare: a new paradigm.

1 reference

12 December 2020

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

1 reference

12 December 2020

External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.185

1 reference

Dimensions Publication ID

29 August 2017

1028334937

0 references

1 reference